#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Auditory verbal hallucinations related to altered long-range synchrony of gamma-band oscillations Our understanding of the neural correlates of auditory-verbal-hallucinations (AVH) has substantially increased during the last few years, but is far from sufficient.
1-1	0-8	Auditory	_
1-2	9-15	verbal	_
1-3	16-30	hallucinations	_
1-4	31-38	related	_
1-5	39-41	to	_
1-6	42-49	altered	_
1-7	50-60	long-range	_
1-8	61-70	synchrony	_
1-9	71-73	of	_
1-10	74-84	gamma-band	_
1-11	85-97	oscillations	_
1-12	98-101	Our	_
1-13	102-115	understanding	_
1-14	116-118	of	_
1-15	119-122	the	_
1-16	123-129	neural	_
1-17	130-140	correlates	_
1-18	141-143	of	_
1-19	144-174	auditory-verbal-hallucinations	_
1-20	175-176	(	_
1-21	177-180	AVH	_
1-22	181-182	)	_
1-23	183-186	has	_
1-24	187-200	substantially	_
1-25	201-210	increased	_
1-26	211-217	during	_
1-27	218-221	the	_
1-28	222-226	last	_
1-29	227-230	few	_
1-30	231-236	years	_
1-31	237-238	,	_
1-32	239-242	but	_
1-33	243-245	is	_
1-34	246-249	far	_
1-35	250-254	from	_
1-36	255-265	sufficient	_
1-37	266-267	.	_

Text=One current hypothesis, the interhemispheric miscommunication theory, is based on findings from fMRI, DTI and EEG, but there is only limited evidence so far concerning underlying functional coupling mechanisms.
2-1	268-271	One	_
2-2	272-279	current	_
2-3	280-290	hypothesis	_
2-4	291-292	,	_
2-5	293-296	the	_
2-6	297-313	interhemispheric	_
2-7	314-330	miscommunication	_
2-8	331-337	theory	_
2-9	338-339	,	_
2-10	340-342	is	_
2-11	343-348	based	_
2-12	349-351	on	_
2-13	352-360	findings	_
2-14	361-365	from	_
2-15	366-370	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-16	371-372	,	_
2-17	373-376	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
2-18	377-380	and	_
2-19	381-384	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
2-20	385-386	,	_
2-21	387-390	but	_
2-22	391-396	there	_
2-23	397-399	is	_
2-24	400-404	only	_
2-25	405-412	limited	_
2-26	413-421	evidence	_
2-27	422-424	so	_
2-28	425-428	far	_
2-29	429-439	concerning	_
2-30	440-450	underlying	_
2-31	451-461	functional	_
2-32	462-470	coupling	_
2-33	471-481	mechanisms	_
2-34	482-483	.	_

Text=Here we report a 64-channel EEG study using lagged phase synchronization analysis and eLORETA source estimation to examine the functional connectivity between bilateral auditory cortices in the gamma-band in 26 schizophrenia patients (13 with and 13 without AVH) and 26 matched healthy controls (HC) while performing a dichotic listening task.
3-1	484-488	Here	_
3-2	489-491	we	_
3-3	492-498	report	_
3-4	499-500	a	_
3-5	501-511	64-channel	_
3-6	512-515	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
3-7	516-521	study	_
3-8	522-527	using	_
3-9	528-534	lagged	_
3-10	535-540	phase	_
3-11	541-556	synchronization	_
3-12	557-565	analysis	_
3-13	566-569	and	_
3-14	570-577	eLORETA	_
3-15	578-584	source	_
3-16	585-595	estimation	_
3-17	596-598	to	_
3-18	599-606	examine	_
3-19	607-610	the	_
3-20	611-621	functional	_
3-21	622-634	connectivity	_
3-22	635-642	between	_
3-23	643-652	bilateral	_
3-24	653-661	auditory	_
3-25	662-670	cortices	_
3-26	671-673	in	_
3-27	674-677	the	_
3-28	678-688	gamma-band	_
3-29	689-691	in	_
3-30	692-694	26	_
3-31	695-708	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-32	709-717	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-33	718-719	(	_
3-34	720-722	13	_
3-35	723-727	with	_
3-36	728-731	and	_
3-37	732-734	13	_
3-38	735-742	without	_
3-39	743-746	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
3-40	747-748	)	_
3-41	749-752	and	_
3-42	753-755	26	_
3-43	756-763	matched	http://maven.renci.org/NeuroBridge/neurobridge#CaseControlStudy
3-44	764-771	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-45	772-780	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-46	781-782	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-47	783-785	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-48	786-787	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
3-49	788-793	while	_
3-50	794-804	performing	_
3-51	805-806	a	_
3-52	807-815	dichotic	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-53	816-825	listening	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-54	826-830	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
3-55	831-832	.	_

Text=We found a significantly reduced right-ear-advantage (REA) in AVH but not in non-AVH patients compared to HC.
4-1	833-835	We	_
4-2	836-841	found	_
4-3	842-843	a	_
4-4	844-857	significantly	_
4-5	858-865	reduced	_
4-6	866-885	right-ear-advantage	_
4-7	886-887	(	_
4-8	888-891	REA	_
4-9	892-893	)	_
4-10	894-896	in	_
4-11	897-900	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-12	901-904	but	_
4-13	905-908	not	_
4-14	909-911	in	_
4-15	912-919	non-AVH	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-16	920-928	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-17	929-937	compared	_
4-18	938-940	to	_
4-19	941-943	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-20	944-945	.	_

Text=The major finding was significantly stronger gamma-band connectivity between bilateral auditory cortices during conscious perception of left (versus right) ear syllables in patients with AVH compared to HC and patients without AVH.
5-1	946-949	The	_
5-2	950-955	major	_
5-3	956-963	finding	_
5-4	964-967	was	_
5-5	968-981	significantly	_
5-6	982-990	stronger	_
5-7	991-1001	gamma-band	_
5-8	1002-1014	connectivity	_
5-9	1015-1022	between	_
5-10	1023-1032	bilateral	_
5-11	1033-1041	auditory	_
5-12	1042-1050	cortices	_
5-13	1051-1057	during	_
5-14	1058-1067	conscious	_
5-15	1068-1078	perception	_
5-16	1079-1081	of	_
5-17	1082-1086	left	_
5-18	1087-1088	(	_
5-19	1089-1095	versus	_
5-20	1096-1101	right	_
5-21	1102-1103	)	_
5-22	1104-1107	ear	_
5-23	1108-1117	syllables	_
5-24	1118-1120	in	_
5-25	1121-1129	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-26	1130-1134	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-27	1135-1138	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-28	1139-1147	compared	_
5-29	1148-1150	to	_
5-30	1151-1153	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-31	1154-1157	and	_
5-32	1158-1166	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-33	1167-1174	without	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-34	1175-1178	AVH	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-35	1179-1180	.	_

Text=A significant positive correlation was found between this connectivity alteration and the AVH symptom score in schizophrenia patients.
6-1	1181-1182	A	_
6-2	1183-1194	significant	_
6-3	1195-1203	positive	_
6-4	1204-1215	correlation	_
6-5	1216-1219	was	_
6-6	1220-1225	found	_
6-7	1226-1233	between	_
6-8	1234-1238	this	_
6-9	1239-1251	connectivity	_
6-10	1252-1262	alteration	_
6-11	1263-1266	and	_
6-12	1267-1270	the	_
6-13	1271-1274	AVH	_
6-14	1275-1282	symptom	_
6-15	1283-1288	score	_
6-16	1289-1291	in	_
6-17	1292-1305	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-18	1306-1314	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-19	1315-1316	.	_

Text=These findings provide further support for the interhemispheric miscommunication hypothesis of AVH pathophysiology by indicating that aberrant gamma-band coupling between auditory cortices is related to the emergence of AVH in schizophrenia.
7-1	1317-1322	These	_
7-2	1323-1331	findings	_
7-3	1332-1339	provide	_
7-4	1340-1347	further	_
7-5	1348-1355	support	_
7-6	1356-1359	for	_
7-7	1360-1363	the	_
7-8	1364-1380	interhemispheric	_
7-9	1381-1397	miscommunication	_
7-10	1398-1408	hypothesis	_
7-11	1409-1411	of	_
7-12	1412-1415	AVH	_
7-13	1416-1431	pathophysiology	_
7-14	1432-1434	by	_
7-15	1435-1445	indicating	_
7-16	1446-1450	that	_
7-17	1451-1459	aberrant	_
7-18	1460-1470	gamma-band	_
7-19	1471-1479	coupling	_
7-20	1480-1487	between	_
7-21	1488-1496	auditory	_
7-22	1497-1505	cortices	_
7-23	1506-1508	is	_
7-24	1509-1516	related	_
7-25	1517-1519	to	_
7-26	1520-1523	the	_
7-27	1524-1533	emergence	_
7-28	1534-1536	of	_
7-29	1537-1540	AVH	_
7-30	1541-1543	in	_
7-31	1544-1557	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-32	1558-1559	.	_

Text=Methods Participants This study included 26 patients who met the DSM-IV criteria for SCZ and 26 healthy controls (HC) matched for age, sex, and education.
8-1	1560-1567	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
8-2	1568-1580	Participants	_
8-3	1581-1585	This	_
8-4	1586-1591	study	_
8-5	1592-1600	included	_
8-6	1601-1603	26	_
8-7	1604-1612	patients	_
8-8	1613-1616	who	_
8-9	1617-1620	met	_
8-10	1621-1624	the	_
8-11	1625-1631	DSM-IV	_
8-12	1632-1640	criteria	_
8-13	1641-1644	for	_
8-14	1645-1648	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-15	1649-1652	and	_
8-16	1653-1655	26	_
8-17	1656-1663	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
8-18	1664-1672	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
8-19	1673-1674	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
8-20	1675-1677	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
8-21	1678-1679	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
8-22	1680-1687	matched	_
8-23	1688-1691	for	_
8-24	1692-1695	age	_
8-25	1696-1697	,	_
8-26	1698-1701	sex	_
8-27	1702-1703	,	_
8-28	1704-1707	and	_
8-29	1708-1717	education	_
8-30	1718-1719	.	_

Text=Inclusion criteria were German as a native language, right-handedness, no current presence and/or history of co-morbidities with axis I and II disorders of the DSM, no neurological disorders, no history of alcohol/drug dependence or abuse within three months, an IQ of ≥70, and no hearing damage or tinnitus.
9-1	1720-1729	Inclusion	_
9-2	1730-1738	criteria	_
9-3	1739-1743	were	_
9-4	1744-1750	German	_
9-5	1751-1753	as	_
9-6	1754-1755	a	_
9-7	1756-1762	native	_
9-8	1763-1771	language	_
9-9	1772-1773	,	_
9-10	1774-1790	right-handedness	_
9-11	1791-1792	,	_
9-12	1793-1795	no	_
9-13	1796-1803	current	_
9-14	1804-1812	presence	_
9-15	1813-1819	and/or	_
9-16	1820-1827	history	_
9-17	1828-1830	of	_
9-18	1831-1845	co-morbidities	_
9-19	1846-1850	with	_
9-20	1851-1855	axis	_
9-21	1856-1857	I	_
9-22	1858-1861	and	_
9-23	1862-1864	II	_
9-24	1865-1874	disorders	_
9-25	1875-1877	of	_
9-26	1878-1881	the	_
9-27	1882-1885	DSM	_
9-28	1886-1887	,	_
9-29	1888-1890	no	_
9-30	1891-1903	neurological	_
9-31	1904-1913	disorders	_
9-32	1914-1915	,	_
9-33	1916-1918	no	_
9-34	1919-1926	history	_
9-35	1927-1929	of	_
9-36	1930-1942	alcohol/drug	_
9-37	1943-1953	dependence	_
9-38	1954-1956	or	_
9-39	1957-1962	abuse	_
9-40	1963-1969	within	_
9-41	1970-1975	three	_
9-42	1976-1982	months	_
9-43	1983-1984	,	_
9-44	1985-1987	an	_
9-45	1988-1990	IQ	_
9-46	1991-1993	of	_
9-47	1994-1997	≥70	_
9-48	1998-1999	,	_
9-49	2000-2003	and	_
9-50	2004-2006	no	_
9-51	2007-2014	hearing	_
9-52	2015-2021	damage	_
9-53	2022-2024	or	_
9-54	2025-2033	tinnitus	_
9-55	2034-2035	.	_

Text=Most patients were taking antipsychotic medications, but there was no medication that would have interfered with EEG, neurological or cognitive functions (e.g.
10-1	2036-2040	Most	_
10-2	2041-2049	patients	_
10-3	2050-2054	were	_
10-4	2055-2061	taking	_
10-5	2062-2075	antipsychotic	_
10-6	2076-2087	medications	_
10-7	2088-2089	,	_
10-8	2090-2093	but	_
10-9	2094-2099	there	_
10-10	2100-2103	was	_
10-11	2104-2106	no	_
10-12	2107-2117	medication	_
10-13	2118-2122	that	_
10-14	2123-2128	would	_
10-15	2129-2133	have	_
10-16	2134-2144	interfered	_
10-17	2145-2149	with	_
10-18	2150-2153	EEG	_
10-19	2154-2155	,	_
10-20	2156-2168	neurological	_
10-21	2169-2171	or	_
10-22	2172-2181	cognitive	_
10-23	2182-2191	functions	_
10-24	2192-2193	(	_
10-25	2194-2197	e.g	_
10-26	2198-2199	.	_

Text=Clozapine; Table 1).
11-1	2200-2209	Clozapine	_
11-2	2210-2211	;	_
11-3	2212-2217	Table	_
11-4	2218-2219	1	_
11-5	2220-2221	)	_
11-6	2222-2223	.	_

Text=Psychopathologic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), which was evaluated according to Gaag et al ..
12-1	2224-2240	Psychopathologic	_
12-2	2241-2249	symptoms	_
12-3	2250-2254	were	_
12-4	2255-2263	assessed	_
12-5	2264-2269	using	_
12-6	2270-2273	the	_
12-7	2274-2282	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-8	2283-2286	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-9	2287-2295	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-10	2296-2304	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-11	2305-2310	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-12	2311-2312	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-13	2313-2318	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-14	2319-2320	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
12-15	2321-2322	,	_
12-16	2323-2328	which	_
12-17	2329-2332	was	_
12-18	2333-2342	evaluated	_
12-19	2343-2352	according	_
12-20	2353-2355	to	_
12-21	2356-2360	Gaag	_
12-22	2361-2363	et	_
12-23	2364-2366	al	_
12-24	2367-2369	..	_

Text=The individual mental state was examined using the subjective well-being under neuroleptic scale (SWN-K).
13-1	2370-2373	The	_
13-2	2374-2384	individual	_
13-3	2385-2391	mental	_
13-4	2392-2397	state	_
13-5	2398-2401	was	_
13-6	2402-2410	examined	_
13-7	2411-2416	using	_
13-8	2417-2420	the	_
13-9	2421-2431	subjective	_
13-10	2432-2442	well-being	_
13-11	2443-2448	under	_
13-12	2449-2460	neuroleptic	_
13-13	2461-2466	scale	_
13-14	2467-2468	(	_
13-15	2469-2474	SWN-K	_
13-16	2475-2476	)	_
13-17	2477-2478	.	_

Text=The patients were carefully assigned according to the current history of AVH using the positive PANSS item “ P3 ” into two groups (AVH vs. non-AVH patients).
14-1	2479-2482	The	_
14-2	2483-2491	patients	_
14-3	2492-2496	were	_
14-4	2497-2506	carefully	_
14-5	2507-2515	assigned	_
14-6	2516-2525	according	_
14-7	2526-2528	to	_
14-8	2529-2532	the	_
14-9	2533-2540	current	_
14-10	2541-2548	history	_
14-11	2549-2551	of	_
14-12	2552-2555	AVH	_
14-13	2556-2561	using	_
14-14	2562-2565	the	_
14-15	2566-2574	positive	_
14-16	2575-2580	PANSS	_
14-17	2581-2585	item	_
14-18	2586-2587	“	_
14-19	2588-2590	P3	_
14-20	2591-2592	”	_
14-21	2593-2597	into	_
14-22	2598-2601	two	_
14-23	2602-2608	groups	_
14-24	2609-2610	(	_
14-25	2611-2614	AVH	_
14-26	2615-2618	vs.	_
14-27	2619-2626	non-AVH	_
14-28	2627-2635	patients	_
14-29	2636-2637	)	_
14-30	2638-2639	.	_

Text=The Psychotic Symptom Rating Scales (PSYRATS) was used to document the phenomenological features of the voices.
15-1	2640-2643	The	_
15-2	2644-2653	Psychotic	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-3	2654-2661	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-4	2662-2668	Rating	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-5	2669-2675	Scales	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-6	2676-2677	(	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-7	2678-2685	PSYRATS	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-8	2686-2687	)	http://maven.renci.org/NeuroBridge/neurobridge#ProdromalSymptomRatingScale
15-9	2688-2691	was	_
15-10	2692-2696	used	_
15-11	2697-2699	to	_
15-12	2700-2708	document	_
15-13	2709-2712	the	_
15-14	2713-2729	phenomenological	_
15-15	2730-2738	features	_
15-16	2739-2741	of	_
15-17	2742-2745	the	_
15-18	2746-2752	voices	_
15-19	2753-2754	.	_

Text=The group of healthy subjects partly overlapped with the sample of our previous study (4 new subjects were recruited for matching).
16-1	2755-2758	The	_
16-2	2759-2764	group	_
16-3	2765-2767	of	_
16-4	2768-2775	healthy	_
16-5	2776-2784	subjects	_
16-6	2785-2791	partly	_
16-7	2792-2802	overlapped	_
16-8	2803-2807	with	_
16-9	2808-2811	the	_
16-10	2812-2818	sample	_
16-11	2819-2821	of	_
16-12	2822-2825	our	_
16-13	2826-2834	previous	_
16-14	2835-2840	study	_
16-15	2841-2842	(	_
16-16	2843-2844	4	_
16-17	2845-2848	new	_
16-18	2849-2857	subjects	_
16-19	2858-2862	were	_
16-20	2863-2872	recruited	_
16-21	2873-2876	for	_
16-22	2877-2885	matching	_
16-23	2886-2887	)	_
16-24	2888-2889	.	_

Text=This study was approved by the ethical committee of Medical Association Hamburg and was consistent with the principles outlined in an internationally recognized standard for ethical conduct in human research.
17-1	2890-2894	This	_
17-2	2895-2900	study	_
17-3	2901-2904	was	_
17-4	2905-2913	approved	_
17-5	2914-2916	by	_
17-6	2917-2920	the	_
17-7	2921-2928	ethical	_
17-8	2929-2938	committee	_
17-9	2939-2941	of	_
17-10	2942-2949	Medical	_
17-11	2950-2961	Association	_
17-12	2962-2969	Hamburg	_
17-13	2970-2973	and	_
17-14	2974-2977	was	_
17-15	2978-2988	consistent	_
17-16	2989-2993	with	_
17-17	2994-2997	the	_
17-18	2998-3008	principles	_
17-19	3009-3017	outlined	_
17-20	3018-3020	in	_
17-21	3021-3023	an	_
17-22	3024-3039	internationally	_
17-23	3040-3050	recognized	_
17-24	3051-3059	standard	_
17-25	3060-3063	for	_
17-26	3064-3071	ethical	_
17-27	3072-3079	conduct	_
17-28	3080-3082	in	_
17-29	3083-3088	human	_
17-30	3089-3097	research	_
17-31	3098-3099	.	_

Text=After participants received a complete description of the experimental procedures, written informed consent was obtained according to the Declaration of Helsinki.
18-1	3100-3105	After	_
18-2	3106-3118	participants	_
18-3	3119-3127	received	_
18-4	3128-3129	a	_
18-5	3130-3138	complete	_
18-6	3139-3150	description	_
18-7	3151-3153	of	_
18-8	3154-3157	the	_
18-9	3158-3170	experimental	_
18-10	3171-3181	procedures	_
18-11	3182-3183	,	_
18-12	3184-3191	written	_
18-13	3192-3200	informed	_
18-14	3201-3208	consent	_
18-15	3209-3212	was	_
18-16	3213-3221	obtained	_
18-17	3222-3231	according	_
18-18	3232-3234	to	_
18-19	3235-3238	the	_
18-20	3239-3250	Declaration	_
18-21	3251-3253	of	_
18-22	3254-3262	Helsinki	_
18-23	3263-3264	.	_

Text=Paradigm The DL task used was the same as in our previous study (for detailed description see ref.
19-1	3265-3273	Paradigm	_
19-2	3274-3277	The	_
19-3	3278-3280	DL	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
19-4	3281-3285	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
19-5	3286-3290	used	_
19-6	3291-3294	was	_
19-7	3295-3298	the	_
19-8	3299-3303	same	_
19-9	3304-3306	as	_
19-10	3307-3309	in	_
19-11	3310-3313	our	_
19-12	3314-3322	previous	_
19-13	3323-3328	study	_
19-14	3329-3330	(	_
19-15	3331-3334	for	_
19-16	3335-3343	detailed	_
19-17	3344-3355	description	_
19-18	3356-3359	see	_
19-19	3360-3363	ref	_
19-20	3364-3365	.	_

Text=and Fig.
20-1	3366-3369	and	_
20-2	3370-3373	Fig	_
20-3	3374-3375	.	_

Text=1).
21-1	3376-3377	1	_
21-2	3378-3379	)	_
21-3	3380-3381	.	_

Text=In brief, six different consonant-vocal syllables (/ba/, /da/, /ka/, /ga/, /pa/, /ta/) were paired and presented simultaneously: one syllable to each ear, resulting in 12 different combinations.
22-1	3382-3384	In	_
22-2	3385-3390	brief	_
22-3	3391-3392	,	_
22-4	3393-3396	six	_
22-5	3397-3406	different	_
22-6	3407-3422	consonant-vocal	_
22-7	3423-3432	syllables	_
22-8	3433-3434	(	_
22-9	3435-3439	/ba/	_
22-10	3440-3441	,	_
22-11	3442-3446	/da/	_
22-12	3447-3448	,	_
22-13	3449-3453	/ka/	_
22-14	3454-3455	,	_
22-15	3456-3460	/ga/	_
22-16	3461-3462	,	_
22-17	3463-3467	/pa/	_
22-18	3468-3469	,	_
22-19	3470-3474	/ta/	_
22-20	3475-3476	)	_
22-21	3477-3481	were	_
22-22	3482-3488	paired	_
22-23	3489-3492	and	_
22-24	3493-3502	presented	_
22-25	3503-3517	simultaneously	_
22-26	3518-3519	:	_
22-27	3520-3523	one	_
22-28	3524-3532	syllable	_
22-29	3533-3535	to	_
22-30	3536-3540	each	_
22-31	3541-3544	ear	_
22-32	3545-3546	,	_
22-33	3547-3556	resulting	_
22-34	3557-3559	in	_
22-35	3560-3562	12	_
22-36	3563-3572	different	_
22-37	3573-3585	combinations	_
22-38	3586-3587	.	_

Text=Participants were instructed to report after each trial which syllable was perceived best.
23-1	3588-3600	Participants	_
23-2	3601-3605	were	_
23-3	3606-3616	instructed	_
23-4	3617-3619	to	_
23-5	3620-3626	report	_
23-6	3627-3632	after	_
23-7	3633-3637	each	_
23-8	3638-3643	trial	_
23-9	3644-3649	which	_
23-10	3650-3658	syllable	_
23-11	3659-3662	was	_
23-12	3663-3672	perceived	_
23-13	3673-3677	best	_
23-14	3678-3679	.	_

Text=The response was given via button press with the right (dominant) hand, while a response screen, which appeared right after hearing the syllable pair, showed all six syllables presented in a circular formation.
24-1	3680-3683	The	_
24-2	3684-3692	response	_
24-3	3693-3696	was	_
24-4	3697-3702	given	_
24-5	3703-3706	via	_
24-6	3707-3713	button	_
24-7	3714-3719	press	_
24-8	3720-3724	with	_
24-9	3725-3728	the	_
24-10	3729-3734	right	_
24-11	3735-3736	(	_
24-12	3737-3745	dominant	_
24-13	3746-3747	)	_
24-14	3748-3752	hand	_
24-15	3753-3754	,	_
24-16	3755-3760	while	_
24-17	3761-3762	a	_
24-18	3763-3771	response	_
24-19	3772-3778	screen	_
24-20	3779-3780	,	_
24-21	3781-3786	which	_
24-22	3787-3795	appeared	_
24-23	3796-3801	right	_
24-24	3802-3807	after	_
24-25	3808-3815	hearing	_
24-26	3816-3819	the	_
24-27	3820-3828	syllable	_
24-28	3829-3833	pair	_
24-29	3834-3835	,	_
24-30	3836-3842	showed	_
24-31	3843-3846	all	_
24-32	3847-3850	six	_
24-33	3851-3860	syllables	_
24-34	3861-3870	presented	_
24-35	3871-3873	in	_
24-36	3874-3875	a	_
24-37	3876-3884	circular	_
24-38	3885-3894	formation	_
24-39	3895-3896	.	_

Text=By clicking with the index finger the left mouse button it was possible to navigate through the six answer alternatives and by clicking with the ring finger the right mouse button the selection was confirmed.
25-1	3897-3899	By	_
25-2	3900-3908	clicking	_
25-3	3909-3913	with	_
25-4	3914-3917	the	_
25-5	3918-3923	index	_
25-6	3924-3930	finger	_
25-7	3931-3934	the	_
25-8	3935-3939	left	_
25-9	3940-3945	mouse	_
25-10	3946-3952	button	_
25-11	3953-3955	it	_
25-12	3956-3959	was	_
25-13	3960-3968	possible	_
25-14	3969-3971	to	_
25-15	3972-3980	navigate	_
25-16	3981-3988	through	_
25-17	3989-3992	the	_
25-18	3993-3996	six	_
25-19	3997-4003	answer	_
25-20	4004-4016	alternatives	_
25-21	4017-4020	and	_
25-22	4021-4023	by	_
25-23	4024-4032	clicking	_
25-24	4033-4037	with	_
25-25	4038-4041	the	_
25-26	4042-4046	ring	_
25-27	4047-4053	finger	_
25-28	4054-4057	the	_
25-29	4058-4063	right	_
25-30	4064-4069	mouse	_
25-31	4070-4076	button	_
25-32	4077-4080	the	_
25-33	4081-4090	selection	_
25-34	4091-4094	was	_
25-35	4095-4104	confirmed	_
25-36	4105-4106	.	_

Text=In order to assess the magnitude of the ear effect, a behavioral laterality index (LI) was calculated for every subject according to the formula: LI = 100 * (RE − LE) / (RE + LE), where RE = number of correct right ear reports and LE = number of correct left ear reports.
26-1	4107-4109	In	_
26-2	4110-4115	order	_
26-3	4116-4118	to	_
26-4	4119-4125	assess	_
26-5	4126-4129	the	_
26-6	4130-4139	magnitude	_
26-7	4140-4142	of	_
26-8	4143-4146	the	_
26-9	4147-4150	ear	_
26-10	4151-4157	effect	_
26-11	4158-4159	,	_
26-12	4160-4161	a	_
26-13	4162-4172	behavioral	_
26-14	4173-4183	laterality	_
26-15	4184-4189	index	_
26-16	4190-4191	(	_
26-17	4192-4194	LI	_
26-18	4195-4196	)	_
26-19	4197-4200	was	_
26-20	4201-4211	calculated	_
26-21	4212-4215	for	_
26-22	4216-4221	every	_
26-23	4222-4229	subject	_
26-24	4230-4239	according	_
26-25	4240-4242	to	_
26-26	4243-4246	the	_
26-27	4247-4254	formula	_
26-28	4255-4256	:	_
26-29	4257-4259	LI	_
26-30	4260-4261	=	_
26-31	4262-4265	100	_
26-32	4266-4267	*	_
26-33	4268-4269	(	_
26-34	4270-4272	RE	_
26-35	4273-4274	−	_
26-36	4275-4277	LE	_
26-37	4278-4279	)	_
26-38	4280-4281	/	_
26-39	4282-4283	(	_
26-40	4284-4286	RE	_
26-41	4287-4288	+	_
26-42	4289-4291	LE	_
26-43	4292-4293	)	_
26-44	4294-4295	,	_
26-45	4296-4301	where	_
26-46	4302-4304	RE	_
26-47	4305-4306	=	_
26-48	4307-4313	number	_
26-49	4314-4316	of	_
26-50	4317-4324	correct	_
26-51	4325-4330	right	_
26-52	4331-4334	ear	_
26-53	4335-4342	reports	_
26-54	4343-4346	and	_
26-55	4347-4349	LE	_
26-56	4350-4351	=	_
26-57	4352-4358	number	_
26-58	4359-4361	of	_
26-59	4362-4369	correct	_
26-60	4370-4374	left	_
26-61	4375-4378	ear	_
26-62	4379-4386	reports	_
26-63	4387-4388	.	_

Text=The scale varies between −100 and +100, with negative values indicating a left-ear advantage (LEA) and positive values indicating a REA.
27-1	4389-4392	The	_
27-2	4393-4398	scale	_
27-3	4399-4405	varies	_
27-4	4406-4413	between	_
27-5	4414-4418	−100	_
27-6	4419-4422	and	_
27-7	4423-4427	+100	_
27-8	4428-4429	,	_
27-9	4430-4434	with	_
27-10	4435-4443	negative	_
27-11	4444-4450	values	_
27-12	4451-4461	indicating	_
27-13	4462-4463	a	_
27-14	4464-4472	left-ear	_
27-15	4473-4482	advantage	_
27-16	4483-4484	(	_
27-17	4485-4488	LEA	_
27-18	4489-4490	)	_
27-19	4491-4494	and	_
27-20	4495-4503	positive	_
27-21	4504-4510	values	_
27-22	4511-4521	indicating	_
27-23	4522-4523	a	_
27-24	4524-4527	REA	_
27-25	4528-4529	.	_

Text=EEG recording and functional connectivity analysis The recording took place in a sound-proof and electrically shielded cabin, while participants listened through closed system headphones (Sennheiser, HAD 200) to the randomly presented 240 syllable pairs at approximately 75 dB.
28-1	4530-4533	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
28-2	4534-4543	recording	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
28-3	4544-4547	and	_
28-4	4548-4558	functional	_
28-5	4559-4571	connectivity	_
28-6	4572-4580	analysis	_
28-7	4581-4584	The	_
28-8	4585-4594	recording	_
28-9	4595-4599	took	_
28-10	4600-4605	place	_
28-11	4606-4608	in	_
28-12	4609-4610	a	_
28-13	4611-4622	sound-proof	_
28-14	4623-4626	and	_
28-15	4627-4639	electrically	_
28-16	4640-4648	shielded	_
28-17	4649-4654	cabin	_
28-18	4655-4656	,	_
28-19	4657-4662	while	_
28-20	4663-4675	participants	_
28-21	4676-4684	listened	_
28-22	4685-4692	through	_
28-23	4693-4699	closed	_
28-24	4700-4706	system	_
28-25	4707-4717	headphones	_
28-26	4718-4719	(	_
28-27	4720-4730	Sennheiser	_
28-28	4731-4732	,	_
28-29	4733-4736	HAD	_
28-30	4737-4740	200	_
28-31	4741-4742	)	_
28-32	4743-4745	to	_
28-33	4746-4749	the	_
28-34	4750-4758	randomly	_
28-35	4759-4768	presented	_
28-36	4769-4772	240	_
28-37	4773-4781	syllable	_
28-38	4782-4787	pairs	_
28-39	4788-4790	at	_
28-40	4791-4804	approximately	_
28-41	4805-4807	75	_
28-42	4808-4810	dB	_
28-43	4811-4812	.	_

Text=The EEG recordings were conducted with 64 Ag/AgCl electrodes mounted on an elastic cap (ActiCaps, Brain Products, Munich, Germany), including four EOG channels to monitor eye movements, using the Brain Vision Recorder 1.10 (Brain Products, Munich, Germany).
29-1	4813-4816	The	_
29-2	4817-4820	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
29-3	4821-4831	recordings	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
29-4	4832-4836	were	_
29-5	4837-4846	conducted	_
29-6	4847-4851	with	_
29-7	4852-4854	64	_
29-8	4855-4862	Ag/AgCl	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-9	4863-4873	electrodes	_
29-10	4874-4881	mounted	_
29-11	4882-4884	on	_
29-12	4885-4887	an	_
29-13	4888-4895	elastic	_
29-14	4896-4899	cap	_
29-15	4900-4901	(	_
29-16	4902-4910	ActiCaps	_
29-17	4911-4912	,	_
29-18	4913-4918	Brain	_
29-19	4919-4927	Products	_
29-20	4928-4929	,	_
29-21	4930-4936	Munich	_
29-22	4937-4938	,	_
29-23	4939-4946	Germany	_
29-24	4947-4948	)	_
29-25	4949-4950	,	_
29-26	4951-4960	including	_
29-27	4961-4965	four	_
29-28	4966-4969	EOG	_
29-29	4970-4978	channels	_
29-30	4979-4981	to	_
29-31	4982-4989	monitor	_
29-32	4990-4993	eye	_
29-33	4994-5003	movements	_
29-34	5004-5005	,	_
29-35	5006-5011	using	_
29-36	5012-5015	the	_
29-37	5016-5021	Brain	_
29-38	5022-5028	Vision	_
29-39	5029-5037	Recorder	_
29-40	5038-5042	1.10	_
29-41	5043-5044	(	_
29-42	5045-5050	Brain	_
29-43	5051-5059	Products	_
29-44	5060-5061	,	_
29-45	5062-5068	Munich	_
29-46	5069-5070	,	_
29-47	5071-5078	Germany	_
29-48	5079-5080	)	_
29-49	5081-5082	.	_

Text=Data were recorded with a bandpass (0.1 to 1000 Hz) and digitized at a sampling rate of 1000 Hz.
30-1	5083-5087	Data	_
30-2	5088-5092	were	_
30-3	5093-5101	recorded	_
30-4	5102-5106	with	_
30-5	5107-5108	a	_
30-6	5109-5117	bandpass	_
30-7	5118-5119	(	_
30-8	5120-5123	0.1	_
30-9	5124-5126	to	_
30-10	5127-5131	1000	_
30-11	5132-5134	Hz	_
30-12	5135-5136	)	_
30-13	5137-5140	and	_
30-14	5141-5150	digitized	_
30-15	5151-5153	at	_
30-16	5154-5155	a	_
30-17	5156-5164	sampling	_
30-18	5165-5169	rate	_
30-19	5170-5172	of	_
30-20	5173-5177	1000	_
30-21	5178-5180	Hz	_
30-22	5181-5182	.	_

Text=Impedances were kept below 5 KΩ.
31-1	5183-5193	Impedances	_
31-2	5194-5198	were	_
31-3	5199-5203	kept	_
31-4	5204-5209	below	_
31-5	5210-5211	5	_
31-6	5212-5214	KΩ	_
31-7	5215-5216	.	_

Text=Offline processing was carried out using Brain Vision Analyzer 2.0 (Brain Products, Munich, Germany).
32-1	5217-5224	Offline	_
32-2	5225-5235	processing	_
32-3	5236-5239	was	_
32-4	5240-5247	carried	_
32-5	5248-5251	out	_
32-6	5252-5257	using	_
32-7	5258-5263	Brain	_
32-8	5264-5270	Vision	_
32-9	5271-5279	Analyzer	_
32-10	5280-5283	2.0	_
32-11	5284-5285	(	_
32-12	5286-5291	Brain	_
32-13	5292-5300	Products	_
32-14	5301-5302	,	_
32-15	5303-5309	Munich	_
32-16	5310-5311	,	_
32-17	5312-5319	Germany	_
32-18	5320-5321	)	_
32-19	5322-5323	.	_

Text=The data was Butterworth zero phase bandpass filtered from 20 to 120 Hz (IIR, 12 dB/octave) and down-sampled to 500 Hz All channels were re-referenced to common average and FCz was recovered as a regular channel.
33-1	5324-5327	The	_
33-2	5328-5332	data	_
33-3	5333-5336	was	_
33-4	5337-5348	Butterworth	_
33-5	5349-5353	zero	_
33-6	5354-5359	phase	_
33-7	5360-5368	bandpass	_
33-8	5369-5377	filtered	_
33-9	5378-5382	from	_
33-10	5383-5385	20	_
33-11	5386-5388	to	_
33-12	5389-5392	120	_
33-13	5393-5395	Hz	_
33-14	5396-5397	(	_
33-15	5398-5401	IIR	_
33-16	5402-5403	,	_
33-17	5404-5406	12	_
33-18	5407-5416	dB/octave	_
33-19	5417-5418	)	_
33-20	5419-5422	and	_
33-21	5423-5435	down-sampled	_
33-22	5436-5438	to	_
33-23	5439-5442	500	_
33-24	5443-5445	Hz	_
33-25	5446-5449	All	_
33-26	5450-5458	channels	_
33-27	5459-5463	were	_
33-28	5464-5477	re-referenced	_
33-29	5478-5480	to	_
33-30	5481-5487	common	_
33-31	5488-5495	average	_
33-32	5496-5499	and	_
33-33	5500-5503	FCz	_
33-34	5504-5507	was	_
33-35	5508-5517	recovered	_
33-36	5518-5520	as	_
33-37	5521-5522	a	_
33-38	5523-5530	regular	_
33-39	5531-5538	channel	_
33-40	5539-5540	.	_

Text=Epochs with muscle artifacts in any channel were identified by visual inspection and rejected from further analysis.
34-1	5541-5547	Epochs	_
34-2	5548-5552	with	_
34-3	5553-5559	muscle	_
34-4	5560-5569	artifacts	_
34-5	5570-5572	in	_
34-6	5573-5576	any	_
34-7	5577-5584	channel	_
34-8	5585-5589	were	_
34-9	5590-5600	identified	_
34-10	5601-5603	by	_
34-11	5604-5610	visual	_
34-12	5611-5621	inspection	_
34-13	5622-5625	and	_
34-14	5626-5634	rejected	_
34-15	5635-5639	from	_
34-16	5640-5647	further	_
34-17	5648-5656	analysis	_
34-18	5657-5658	.	_

Text=Independent component analysis (ICA) was applied to identify and remove blink, horizontal eye movements, electrocardiographic, muscle and saccadic spike potential (SP) artifacts based on their characteristic topographies, time-courses, and frequency distributions.
35-1	5659-5670	Independent	_
35-2	5671-5680	component	_
35-3	5681-5689	analysis	_
35-4	5690-5691	(	_
35-5	5692-5695	ICA	_
35-6	5696-5697	)	_
35-7	5698-5701	was	_
35-8	5702-5709	applied	_
35-9	5710-5712	to	_
35-10	5713-5721	identify	_
35-11	5722-5725	and	_
35-12	5726-5732	remove	_
35-13	5733-5738	blink	_
35-14	5739-5740	,	_
35-15	5741-5751	horizontal	_
35-16	5752-5755	eye	_
35-17	5756-5765	movements	_
35-18	5766-5767	,	_
35-19	5768-5788	electrocardiographic	_
35-20	5789-5790	,	_
35-21	5791-5797	muscle	_
35-22	5798-5801	and	_
35-23	5802-5810	saccadic	_
35-24	5811-5816	spike	_
35-25	5817-5826	potential	_
35-26	5827-5828	(	_
35-27	5829-5831	SP	_
35-28	5832-5833	)	_
35-29	5834-5843	artifacts	_
35-30	5844-5849	based	_
35-31	5850-5852	on	_
35-32	5853-5858	their	_
35-33	5859-5873	characteristic	_
35-34	5874-5886	topographies	_
35-35	5887-5888	,	_
35-36	5889-5901	time-courses	_
35-37	5902-5903	,	_
35-38	5904-5907	and	_
35-39	5908-5917	frequency	_
35-40	5918-5931	distributions	_
35-41	5932-5933	.	_

Text=To control for saccadic SPs in the gamma frequency range an additional “ radial electro-oculogram channel ” (REOG) was derived following the procedure described by Keren et al ..
36-1	5934-5936	To	_
36-2	5937-5944	control	_
36-3	5945-5948	for	_
36-4	5949-5957	saccadic	_
36-5	5958-5961	SPs	_
36-6	5962-5964	in	_
36-7	5965-5968	the	_
36-8	5969-5974	gamma	_
36-9	5975-5984	frequency	_
36-10	5985-5990	range	_
36-11	5991-5993	an	_
36-12	5994-6004	additional	_
36-13	6005-6006	“	_
36-14	6007-6013	radial	_
36-15	6014-6031	electro-oculogram	_
36-16	6032-6039	channel	_
36-17	6040-6041	”	_
36-18	6042-6043	(	_
36-19	6044-6048	REOG	_
36-20	6049-6050	)	_
36-21	6051-6054	was	_
36-22	6055-6062	derived	_
36-23	6063-6072	following	_
36-24	6073-6076	the	_
36-25	6077-6086	procedure	_
36-26	6087-6096	described	_
36-27	6097-6099	by	_
36-28	6100-6105	Keren	_
36-29	6106-6108	et	_
36-30	6109-6111	al	_
36-31	6112-6114	..	_

Text=Subsequently, the artifact-free data was segmented in epochs ranging from −200 to 1848 ms regarding the stimulus onset and sorted as RE or LE reports.
37-1	6115-6127	Subsequently	_
37-2	6128-6129	,	_
37-3	6130-6133	the	_
37-4	6134-6147	artifact-free	_
37-5	6148-6152	data	_
37-6	6153-6156	was	_
37-7	6157-6166	segmented	_
37-8	6167-6169	in	_
37-9	6170-6176	epochs	_
37-10	6177-6184	ranging	_
37-11	6185-6189	from	_
37-12	6190-6194	−200	_
37-13	6195-6197	to	_
37-14	6198-6202	1848	_
37-15	6203-6205	ms	_
37-16	6206-6215	regarding	_
37-17	6216-6219	the	_
37-18	6220-6228	stimulus	_
37-19	6229-6234	onset	_
37-20	6235-6238	and	_
37-21	6239-6245	sorted	_
37-22	6246-6248	as	_
37-23	6249-6251	RE	_
37-24	6252-6254	or	_
37-25	6255-6257	LE	_
37-26	6258-6265	reports	_
37-27	6266-6267	.	_

Text=Finally, the number of correct-response epochs were exported for further analysis and balanced between LE and RE reports for every subject (matched number of trials for AVH: 68.23 ± 19.43; non-AVH: 68.76 ± 14.79 and HC: 71.19 ± 12.93), with no significant difference in the number of trials between the three groups [F (1,51) = 0.208, p = 0.81].
38-1	6268-6275	Finally	_
38-2	6276-6277	,	_
38-3	6278-6281	the	_
38-4	6282-6288	number	_
38-5	6289-6291	of	_
38-6	6292-6308	correct-response	_
38-7	6309-6315	epochs	_
38-8	6316-6320	were	_
38-9	6321-6329	exported	_
38-10	6330-6333	for	_
38-11	6334-6341	further	_
38-12	6342-6350	analysis	_
38-13	6351-6354	and	_
38-14	6355-6363	balanced	_
38-15	6364-6371	between	_
38-16	6372-6374	LE	_
38-17	6375-6378	and	_
38-18	6379-6381	RE	_
38-19	6382-6389	reports	_
38-20	6390-6393	for	_
38-21	6394-6399	every	_
38-22	6400-6407	subject	_
38-23	6408-6409	(	_
38-24	6410-6417	matched	_
38-25	6418-6424	number	_
38-26	6425-6427	of	_
38-27	6428-6434	trials	_
38-28	6435-6438	for	_
38-29	6439-6442	AVH	_
38-30	6443-6444	:	_
38-31	6445-6450	68.23	_
38-32	6451-6452	±	_
38-33	6453-6458	19.43	_
38-34	6459-6460	;	_
38-35	6461-6468	non-AVH	_
38-36	6469-6470	:	_
38-37	6471-6476	68.76	_
38-38	6477-6478	±	_
38-39	6479-6484	14.79	_
38-40	6485-6488	and	_
38-41	6489-6491	HC	_
38-42	6492-6493	:	_
38-43	6494-6499	71.19	_
38-44	6500-6501	±	_
38-45	6502-6507	12.93	_
38-46	6508-6509	)	_
38-47	6510-6511	,	_
38-48	6512-6516	with	_
38-49	6517-6519	no	_
38-50	6520-6531	significant	_
38-51	6532-6542	difference	_
38-52	6543-6545	in	_
38-53	6546-6549	the	_
38-54	6550-6556	number	_
38-55	6557-6559	of	_
38-56	6560-6566	trials	_
38-57	6567-6574	between	_
38-58	6575-6578	the	_
38-59	6579-6584	three	_
38-60	6585-6591	groups	_
38-61	6592-6593	[	_
38-62	6594-6595	F	_
38-63	6596-6597	(	_
38-64	6598-6602	1,51	_
38-65	6603-6604	)	_
38-66	6605-6606	=	_
38-67	6607-6612	0.208	_
38-68	6613-6614	,	_
38-69	6615-6616	p	_
38-70	6617-6618	=	_
38-71	6619-6623	0.81	_
38-72	6624-6625	]	_
38-73	6626-6627	.	_

Text=Similar to our previous studies, all further analyses were executed with the LORETA KEY software package investigating functional connectivity computed as “ lagged phase synchronization ” (LPS).
39-1	6628-6635	Similar	_
39-2	6636-6638	to	_
39-3	6639-6642	our	_
39-4	6643-6651	previous	_
39-5	6652-6659	studies	_
39-6	6660-6661	,	_
39-7	6662-6665	all	_
39-8	6666-6673	further	_
39-9	6674-6682	analyses	_
39-10	6683-6687	were	_
39-11	6688-6696	executed	_
39-12	6697-6701	with	_
39-13	6702-6705	the	_
39-14	6706-6712	LORETA	_
39-15	6713-6716	KEY	_
39-16	6717-6725	software	_
39-17	6726-6733	package	_
39-18	6734-6747	investigating	_
39-19	6748-6758	functional	_
39-20	6759-6771	connectivity	_
39-21	6772-6780	computed	_
39-22	6781-6783	as	_
39-23	6784-6785	“	_
39-24	6786-6792	lagged	_
39-25	6793-6798	phase	_
39-26	6799-6814	synchronization	_
39-27	6815-6816	”	_
39-28	6817-6818	(	_
39-29	6819-6822	LPS	_
39-30	6823-6824	)	_
39-31	6825-6826	.	_

Text=LPS was assessed within two a priori defined regions-of-interests (ROIs), which have been identified as essential nodes in the AVH network: right and left primary auditory cortices (PACs/BA41) known to support any type of sound processing, and right and left secondary auditory cortices (SACs/BA42) known to be involved in the processing of complex sounds and speech sounds.
40-1	6827-6830	LPS	_
40-2	6831-6834	was	_
40-3	6835-6843	assessed	_
40-4	6844-6850	within	_
40-5	6851-6854	two	_
40-6	6855-6856	a	_
40-7	6857-6863	priori	_
40-8	6864-6871	defined	_
40-9	6872-6892	regions-of-interests	_
40-10	6893-6894	(	_
40-11	6895-6899	ROIs	_
40-12	6900-6901	)	_
40-13	6902-6903	,	_
40-14	6904-6909	which	_
40-15	6910-6914	have	_
40-16	6915-6919	been	_
40-17	6920-6930	identified	_
40-18	6931-6933	as	_
40-19	6934-6943	essential	_
40-20	6944-6949	nodes	_
40-21	6950-6952	in	_
40-22	6953-6956	the	_
40-23	6957-6960	AVH	_
40-24	6961-6968	network	_
40-25	6969-6970	:	_
40-26	6971-6976	right	_
40-27	6977-6980	and	_
40-28	6981-6985	left	_
40-29	6986-6993	primary	_
40-30	6994-7002	auditory	_
40-31	7003-7011	cortices	_
40-32	7012-7013	(	_
40-33	7014-7023	PACs/BA41	_
40-34	7024-7025	)	_
40-35	7026-7031	known	_
40-36	7032-7034	to	_
40-37	7035-7042	support	_
40-38	7043-7046	any	_
40-39	7047-7051	type	_
40-40	7052-7054	of	_
40-41	7055-7060	sound	_
40-42	7061-7071	processing	_
40-43	7072-7073	,	_
40-44	7074-7077	and	_
40-45	7078-7083	right	_
40-46	7084-7087	and	_
40-47	7088-7092	left	_
40-48	7093-7102	secondary	_
40-49	7103-7111	auditory	_
40-50	7112-7120	cortices	_
40-51	7121-7122	(	_
40-52	7123-7132	SACs/BA42	_
40-53	7133-7134	)	_
40-54	7135-7140	known	_
40-55	7141-7143	to	_
40-56	7144-7146	be	_
40-57	7147-7155	involved	_
40-58	7156-7158	in	_
40-59	7159-7162	the	_
40-60	7163-7173	processing	_
40-61	7174-7176	of	_
40-62	7177-7184	complex	_
40-63	7185-7191	sounds	_
40-64	7192-7195	and	_
40-65	7196-7202	speech	_
40-66	7203-7209	sounds	_
40-67	7210-7211	.	_

Text=The ROIs were defined using the anatomical definitions provided by the eLORETA software based on the Talairach Daemon (see Figure S1).
41-1	7212-7215	The	_
41-2	7216-7220	ROIs	_
41-3	7221-7225	were	_
41-4	7226-7233	defined	_
41-5	7234-7239	using	_
41-6	7240-7243	the	_
41-7	7244-7254	anatomical	_
41-8	7255-7266	definitions	_
41-9	7267-7275	provided	_
41-10	7276-7278	by	_
41-11	7279-7282	the	_
41-12	7283-7290	eLORETA	_
41-13	7291-7299	software	_
41-14	7300-7305	based	_
41-15	7306-7308	on	_
41-16	7309-7312	the	_
41-17	7313-7322	Talairach	_
41-18	7323-7329	Daemon	_
41-19	7330-7331	(	_
41-20	7332-7335	see	_
41-21	7336-7342	Figure	_
41-22	7343-7345	S1	_
41-23	7346-7347	)	_
41-24	7348-7349	.	_

Text=Based on our previous work, where we did not find LPS differences in any of the other frequencies (delta, theta, alpha, beta) as well as an effect in all gamma subbands (30–50 Hz, 50–90 Hz), analysis was focused on the whole gamma-band range (30–100 Hz) and the two conditions: LE and RE report.
42-1	7350-7355	Based	_
42-2	7356-7358	on	_
42-3	7359-7362	our	_
42-4	7363-7371	previous	_
42-5	7372-7376	work	_
42-6	7377-7378	,	_
42-7	7379-7384	where	_
42-8	7385-7387	we	_
42-9	7388-7391	did	_
42-10	7392-7395	not	_
42-11	7396-7400	find	_
42-12	7401-7404	LPS	_
42-13	7405-7416	differences	_
42-14	7417-7419	in	_
42-15	7420-7423	any	_
42-16	7424-7426	of	_
42-17	7427-7430	the	_
42-18	7431-7436	other	_
42-19	7437-7448	frequencies	_
42-20	7449-7450	(	_
42-21	7451-7456	delta	_
42-22	7457-7458	,	_
42-23	7459-7464	theta	_
42-24	7465-7466	,	_
42-25	7467-7472	alpha	_
42-26	7473-7474	,	_
42-27	7475-7479	beta	_
42-28	7480-7481	)	_
42-29	7482-7484	as	_
42-30	7485-7489	well	_
42-31	7490-7492	as	_
42-32	7493-7495	an	_
42-33	7496-7502	effect	_
42-34	7503-7505	in	_
42-35	7506-7509	all	_
42-36	7510-7515	gamma	_
42-37	7516-7524	subbands	_
42-38	7525-7526	(	_
42-39	7527-7532	30–50	_
42-40	7533-7535	Hz	_
42-41	7536-7537	,	_
42-42	7538-7543	50–90	_
42-43	7544-7546	Hz	_
42-44	7547-7548	)	_
42-45	7549-7550	,	_
42-46	7551-7559	analysis	_
42-47	7560-7563	was	_
42-48	7564-7571	focused	_
42-49	7572-7574	on	_
42-50	7575-7578	the	_
42-51	7579-7584	whole	_
42-52	7585-7595	gamma-band	_
42-53	7596-7601	range	_
42-54	7602-7603	(	_
42-55	7604-7610	30–100	_
42-56	7611-7613	Hz	_
42-57	7614-7615	)	_
42-58	7616-7619	and	_
42-59	7620-7623	the	_
42-60	7624-7627	two	_
42-61	7628-7638	conditions	_
42-62	7639-7640	:	_
42-63	7641-7643	LE	_
42-64	7644-7647	and	_
42-65	7648-7650	RE	_
42-66	7651-7657	report	_
42-67	7658-7659	.	_

Text=LPS across all the voxels included in the ROIs was based on the average of all LPS values, which were calculated for the connectivity between every voxel of ROI A and every voxel of ROI B.
43-1	7660-7663	LPS	_
43-2	7664-7670	across	_
43-3	7671-7674	all	_
43-4	7675-7678	the	_
43-5	7679-7685	voxels	_
43-6	7686-7694	included	_
43-7	7695-7697	in	_
43-8	7698-7701	the	_
43-9	7702-7706	ROIs	_
43-10	7707-7710	was	_
43-11	7711-7716	based	_
43-12	7717-7719	on	_
43-13	7720-7723	the	_
43-14	7724-7731	average	_
43-15	7732-7734	of	_
43-16	7735-7738	all	_
43-17	7739-7742	LPS	_
43-18	7743-7749	values	_
43-19	7750-7751	,	_
43-20	7752-7757	which	_
43-21	7758-7762	were	_
43-22	7763-7773	calculated	_
43-23	7774-7777	for	_
43-24	7778-7781	the	_
43-25	7782-7794	connectivity	_
43-26	7795-7802	between	_
43-27	7803-7808	every	_
43-28	7809-7814	voxel	_
43-29	7815-7817	of	_
43-30	7818-7821	ROI	_
43-31	7822-7823	A	_
43-32	7824-7827	and	_
43-33	7828-7833	every	_
43-34	7834-7839	voxel	_
43-35	7840-7842	of	_
43-36	7843-7846	ROI	_
43-37	7847-7848	B	_
43-38	7849-7850	.	_

Text=For all single trials, time-varying frequency analysis was done using a short time Fourier transform (sliding Bartlett-Hann window function) with a window width of 100 ms. LPS was calculated using cross spectra derived from that transformation.
44-1	7851-7854	For	_
44-2	7855-7858	all	_
44-3	7859-7865	single	_
44-4	7866-7872	trials	_
44-5	7873-7874	,	_
44-6	7875-7887	time-varying	_
44-7	7888-7897	frequency	_
44-8	7898-7906	analysis	_
44-9	7907-7910	was	_
44-10	7911-7915	done	_
44-11	7916-7921	using	_
44-12	7922-7923	a	_
44-13	7924-7929	short	_
44-14	7930-7934	time	_
44-15	7935-7942	Fourier	_
44-16	7943-7952	transform	_
44-17	7953-7954	(	_
44-18	7955-7962	sliding	_
44-19	7963-7976	Bartlett-Hann	_
44-20	7977-7983	window	_
44-21	7984-7992	function	_
44-22	7993-7994	)	_
44-23	7995-7999	with	_
44-24	8000-8001	a	_
44-25	8002-8008	window	_
44-26	8009-8014	width	_
44-27	8015-8017	of	_
44-28	8018-8021	100	_
44-29	8022-8025	ms.	_
44-30	8026-8029	LPS	_
44-31	8030-8033	was	_
44-32	8034-8044	calculated	_
44-33	8045-8050	using	_
44-34	8051-8056	cross	_
44-35	8057-8064	spectra	_
44-36	8065-8072	derived	_
44-37	8073-8077	from	_
44-38	8078-8082	that	_
44-39	8083-8097	transformation	_
44-40	8098-8099	.	_

Text=In a time frame from 0 to 900 ms after stimulus presentation results were extracted every 100 ms.
45-1	8100-8102	In	_
45-2	8103-8104	a	_
45-3	8105-8109	time	_
45-4	8110-8115	frame	_
45-5	8116-8120	from	_
45-6	8121-8122	0	_
45-7	8123-8125	to	_
45-8	8126-8129	900	_
45-9	8130-8132	ms	_
45-10	8133-8138	after	_
45-11	8139-8147	stimulus	_
45-12	8148-8160	presentation	_
45-13	8161-8168	results	_
45-14	8169-8173	were	_
45-15	8174-8183	extracted	_
45-16	8184-8189	every	_
45-17	8190-8193	100	_
45-18	8194-8196	ms	_
45-19	8197-8198	.	_

Text=Details of EEG electrode placement, the computation methods and its advantages have been provided previously and can be found also in supplementary material.
46-1	8199-8206	Details	_
46-2	8207-8209	of	_
46-3	8210-8213	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
46-4	8214-8223	electrode	_
46-5	8224-8233	placement	_
46-6	8234-8235	,	_
46-7	8236-8239	the	_
46-8	8240-8251	computation	_
46-9	8252-8259	methods	_
46-10	8260-8263	and	_
46-11	8264-8267	its	_
46-12	8268-8278	advantages	_
46-13	8279-8283	have	_
46-14	8284-8288	been	_
46-15	8289-8297	provided	_
46-16	8298-8308	previously	_
46-17	8309-8312	and	_
46-18	8313-8316	can	_
46-19	8317-8319	be	_
46-20	8320-8325	found	_
46-21	8326-8330	also	_
46-22	8331-8333	in	_
46-23	8334-8347	supplementary	_
46-24	8348-8356	material	_
46-25	8357-8358	.	_

Text=Statistics First, the patient groups were compared by means of independent t-tests or Mann-Whitney-U tests (depending on normal distribution and corrected for multiple testing) for clinical data using SPSS 21.
47-1	8359-8369	Statistics	_
47-2	8370-8375	First	_
47-3	8376-8377	,	_
47-4	8378-8381	the	_
47-5	8382-8389	patient	_
47-6	8390-8396	groups	_
47-7	8397-8401	were	_
47-8	8402-8410	compared	_
47-9	8411-8413	by	_
47-10	8414-8419	means	_
47-11	8420-8422	of	_
47-12	8423-8434	independent	_
47-13	8435-8442	t-tests	_
47-14	8443-8445	or	_
47-15	8446-8460	Mann-Whitney-U	_
47-16	8461-8466	tests	_
47-17	8467-8468	(	_
47-18	8469-8478	depending	_
47-19	8479-8481	on	_
47-20	8482-8488	normal	_
47-21	8489-8501	distribution	_
47-22	8502-8505	and	_
47-23	8506-8515	corrected	_
47-24	8516-8519	for	_
47-25	8520-8528	multiple	_
47-26	8529-8536	testing	_
47-27	8537-8538	)	_
47-28	8539-8542	for	_
47-29	8543-8551	clinical	_
47-30	8552-8556	data	_
47-31	8557-8562	using	_
47-32	8563-8567	SPSS	_
47-33	8568-8570	21	_
47-34	8571-8572	.	_

Text=In order to compare demographic and behavioural data across the three groups (HC, AVH, and non-AVH) one-way ANOVA was used with follow-up Bonferroni post-hoc analysis.
48-1	8573-8575	In	_
48-2	8576-8581	order	_
48-3	8582-8584	to	_
48-4	8585-8592	compare	_
48-5	8593-8604	demographic	_
48-6	8605-8608	and	_
48-7	8609-8620	behavioural	_
48-8	8621-8625	data	_
48-9	8626-8632	across	_
48-10	8633-8636	the	_
48-11	8637-8642	three	_
48-12	8643-8649	groups	_
48-13	8650-8651	(	_
48-14	8652-8654	HC	_
48-15	8655-8656	,	_
48-16	8657-8660	AVH	_
48-17	8661-8662	,	_
48-18	8663-8666	and	_
48-19	8667-8674	non-AVH	_
48-20	8675-8676	)	_
48-21	8677-8684	one-way	_
48-22	8685-8690	ANOVA	_
48-23	8691-8694	was	_
48-24	8695-8699	used	_
48-25	8700-8704	with	_
48-26	8705-8714	follow-up	_
48-27	8715-8725	Bonferroni	_
48-28	8726-8734	post-hoc	_
48-29	8735-8743	analysis	_
48-30	8744-8745	.	_

Text=Effect sizes were calculated as r (for Mann-Whitney-U tests) or partial Eta-squared (η 2/for one-way ANOVA).
49-1	8746-8752	Effect	_
49-2	8753-8758	sizes	_
49-3	8759-8763	were	_
49-4	8764-8774	calculated	_
49-5	8775-8777	as	_
49-6	8778-8779	r	_
49-7	8780-8781	(	_
49-8	8782-8785	for	_
49-9	8786-8800	Mann-Whitney-U	_
49-10	8801-8806	tests	_
49-11	8807-8808	)	_
49-12	8809-8811	or	_
49-13	8812-8819	partial	_
49-14	8820-8831	Eta-squared	_
49-15	8832-8833	(	_
49-16	8834-8835	η	_
49-17	8836-8841	2/for	_
49-18	8842-8849	one-way	_
49-19	8850-8855	ANOVA	_
49-20	8856-8857	)	_
49-21	8858-8859	.	_

Text=The effects of group, ROIs, condition, and time on gamma synchrony were assessed with a linear mixed-effects model.
50-1	8860-8863	The	_
50-2	8864-8871	effects	_
50-3	8872-8874	of	_
50-4	8875-8880	group	_
50-5	8881-8882	,	_
50-6	8883-8887	ROIs	_
50-7	8888-8889	,	_
50-8	8890-8899	condition	_
50-9	8900-8901	,	_
50-10	8902-8905	and	_
50-11	8906-8910	time	_
50-12	8911-8913	on	_
50-13	8914-8919	gamma	_
50-14	8920-8929	synchrony	_
50-15	8930-8934	were	_
50-16	8935-8943	assessed	_
50-17	8944-8948	with	_
50-18	8949-8950	a	_
50-19	8951-8957	linear	_
50-20	8958-8971	mixed-effects	_
50-21	8972-8977	model	_
50-22	8978-8979	.	_

Text=Linear mixed models have several advantages over traditional repeated-measures designs, as they can accommodate departures from the assumptions of homogeneity of regression slopes and independence, and thus are better suited to model interindividual variability.
51-1	8980-8986	Linear	_
51-2	8987-8992	mixed	_
51-3	8993-8999	models	_
51-4	9000-9004	have	_
51-5	9005-9012	several	_
51-6	9013-9023	advantages	_
51-7	9024-9028	over	_
51-8	9029-9040	traditional	_
51-9	9041-9058	repeated-measures	_
51-10	9059-9066	designs	_
51-11	9067-9068	,	_
51-12	9069-9071	as	_
51-13	9072-9076	they	_
51-14	9077-9080	can	_
51-15	9081-9092	accommodate	_
51-16	9093-9103	departures	_
51-17	9104-9108	from	_
51-18	9109-9112	the	_
51-19	9113-9124	assumptions	_
51-20	9125-9127	of	_
51-21	9128-9139	homogeneity	_
51-22	9140-9142	of	_
51-23	9143-9153	regression	_
51-24	9154-9160	slopes	_
51-25	9161-9164	and	_
51-26	9165-9177	independence	_
51-27	9178-9179	,	_
51-28	9180-9183	and	_
51-29	9184-9188	thus	_
51-30	9189-9192	are	_
51-31	9193-9199	better	_
51-32	9200-9206	suited	_
51-33	9207-9209	to	_
51-34	9210-9215	model	_
51-35	9216-9231	interindividual	_
51-36	9232-9243	variability	_
51-37	9244-9245	.	_

Text=This model has also been successfully implemented by researchers to analyse EEG data.
52-1	9246-9250	This	_
52-2	9251-9256	model	_
52-3	9257-9260	has	_
52-4	9261-9265	also	_
52-5	9266-9270	been	_
52-6	9271-9283	successfully	_
52-7	9284-9295	implemented	_
52-8	9296-9298	by	_
52-9	9299-9310	researchers	_
52-10	9311-9313	to	_
52-11	9314-9321	analyse	_
52-12	9322-9325	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
52-13	9326-9330	data	_
52-14	9331-9332	.	_

Text=In this study, the model included Group (3 levels: HC, AVH, non-AVH), Time (10 levels: from 0 to 900 ms in 100 ms steps), Condition (2 levels: LE and RE reports), and ROIs (2 levels: BA41, BA42) as the fixed-effects factors, Subject as a random-effects factor, and Gamma Synchrony as the dependent variable.
53-1	9333-9335	In	_
53-2	9336-9340	this	_
53-3	9341-9346	study	_
53-4	9347-9348	,	_
53-5	9349-9352	the	_
53-6	9353-9358	model	_
53-7	9359-9367	included	_
53-8	9368-9373	Group	_
53-9	9374-9375	(	_
53-10	9376-9377	3	_
53-11	9378-9384	levels	_
53-12	9385-9386	:	_
53-13	9387-9389	HC	_
53-14	9390-9391	,	_
53-15	9392-9395	AVH	_
53-16	9396-9397	,	_
53-17	9398-9405	non-AVH	_
53-18	9406-9407	)	_
53-19	9408-9409	,	_
53-20	9410-9414	Time	_
53-21	9415-9416	(	_
53-22	9417-9419	10	_
53-23	9420-9426	levels	_
53-24	9427-9428	:	_
53-25	9429-9433	from	_
53-26	9434-9435	0	_
53-27	9436-9438	to	_
53-28	9439-9442	900	_
53-29	9443-9445	ms	_
53-30	9446-9448	in	_
53-31	9449-9452	100	_
53-32	9453-9455	ms	_
53-33	9456-9461	steps	_
53-34	9462-9463	)	_
53-35	9464-9465	,	_
53-36	9466-9475	Condition	_
53-37	9476-9477	(	_
53-38	9478-9479	2	_
53-39	9480-9486	levels	_
53-40	9487-9488	:	_
53-41	9489-9491	LE	_
53-42	9492-9495	and	_
53-43	9496-9498	RE	_
53-44	9499-9506	reports	_
53-45	9507-9508	)	_
53-46	9509-9510	,	_
53-47	9511-9514	and	_
53-48	9515-9519	ROIs	_
53-49	9520-9521	(	_
53-50	9522-9523	2	_
53-51	9524-9530	levels	_
53-52	9531-9532	:	_
53-53	9533-9537	BA41	_
53-54	9538-9539	,	_
53-55	9540-9544	BA42	_
53-56	9545-9546	)	_
53-57	9547-9549	as	_
53-58	9550-9553	the	_
53-59	9554-9567	fixed-effects	_
53-60	9568-9575	factors	_
53-61	9576-9577	,	_
53-62	9578-9585	Subject	_
53-63	9586-9588	as	_
53-64	9589-9590	a	_
53-65	9591-9605	random-effects	_
53-66	9606-9612	factor	_
53-67	9613-9614	,	_
53-68	9615-9618	and	_
53-69	9619-9624	Gamma	_
53-70	9625-9634	Synchrony	_
53-71	9635-9637	as	_
53-72	9638-9641	the	_
53-73	9642-9651	dependent	_
53-74	9652-9660	variable	_
53-75	9661-9662	.	_

Text=The Spearman ’ s correlation coefficient (two-tailed, p <0.05) was used to investigate the relation between gamma synchrony (LPS difference between LE and RE reports at 600ms), PANSS hallucination item “ P3 ”, and medication dosage in CPZ equivalents, without applying correction for multiple testing as the analysis was considered exploratory.
54-1	9663-9666	The	_
54-2	9667-9675	Spearman	_
54-3	9676-9677	’	_
54-4	9678-9679	s	_
54-5	9680-9691	correlation	_
54-6	9692-9703	coefficient	_
54-7	9704-9705	(	_
54-8	9706-9716	two-tailed	_
54-9	9717-9718	,	_
54-10	9719-9720	p	_
54-11	9721-9722	<	_
54-12	9723-9727	0.05	_
54-13	9728-9729	)	_
54-14	9730-9733	was	_
54-15	9734-9738	used	_
54-16	9739-9741	to	_
54-17	9742-9753	investigate	_
54-18	9754-9757	the	_
54-19	9758-9766	relation	_
54-20	9767-9774	between	_
54-21	9775-9780	gamma	_
54-22	9781-9790	synchrony	_
54-23	9791-9792	(	_
54-24	9793-9796	LPS	_
54-25	9797-9807	difference	_
54-26	9808-9815	between	_
54-27	9816-9818	LE	_
54-28	9819-9822	and	_
54-29	9823-9825	RE	_
54-30	9826-9833	reports	_
54-31	9834-9836	at	_
54-32	9837-9842	600ms	_
54-33	9843-9844	)	_
54-34	9845-9846	,	_
54-35	9847-9852	PANSS	_
54-36	9853-9866	hallucination	_
54-37	9867-9871	item	_
54-38	9872-9873	“	_
54-39	9874-9876	P3	_
54-40	9877-9878	”	_
54-41	9879-9880	,	_
54-42	9881-9884	and	_
54-43	9885-9895	medication	_
54-44	9896-9902	dosage	_
54-45	9903-9905	in	_
54-46	9906-9909	CPZ	_
54-47	9910-9921	equivalents	_
54-48	9922-9923	,	_
54-49	9924-9931	without	_
54-50	9932-9940	applying	_
54-51	9941-9951	correction	_
54-52	9952-9955	for	_
54-53	9956-9964	multiple	_
54-54	9965-9972	testing	_
54-55	9973-9975	as	_
54-56	9976-9979	the	_
54-57	9980-9988	analysis	_
54-58	9989-9992	was	_
54-59	9993-10003	considered	_
54-60	10004-10015	exploratory	_
54-61	10016-10017	.	_

Text=Bootstrapping was used to calculate 95% confidence intervals (CI) around each significant correlation.
55-1	10018-10031	Bootstrapping	_
55-2	10032-10035	was	_
55-3	10036-10040	used	_
55-4	10041-10043	to	_
55-5	10044-10053	calculate	_
55-6	10054-10056	95	_
55-7	10057-10058	%	_
55-8	10059-10069	confidence	_
55-9	10070-10079	intervals	_
55-10	10080-10081	(	_
55-11	10082-10084	CI	_
55-12	10085-10086	)	_
55-13	10087-10093	around	_
55-14	10094-10098	each	_
55-15	10099-10110	significant	_
55-16	10111-10122	correlation	_
55-17	10123-10124	.	_

